The therapeutic efficacy of depleting B cells with rituximab and blocking CD4+ T cell co-stimulation with abatacept (CTLA4-Ig) strongly support a strong contribution of B and T cells leading to the production of autoantibodies to the pathogenesis of RA (23). This evidence concerns the gene CTLA4 and rheumatoid arthritis.